典型慢性髓性白血病中的e19a2 BCR-ABL融合转录本：两例报告
e19a2 BCR-ABL fusion transcript in typical chronic myeloid leukaemia: a report of two cases.
作者信息
Mondal B C, Majumdar S, Dasgupta U B, Chaudhuri U, Chakrabarti P, Bhattacharyya S
机构信息
Department of Biophysics, Molecular Biology and Genetics, University of Calcutta, Kolkata, India.
出版信息
J Clin Pathol. 2006 Oct;59(10):1102-3. doi: 10.1136/jcp.2005.029595.
Abstract
This report describes two patients with chronic myeloid leukaemia (CML): one of them developed accelerated phase CML and died 8 years after diagnosis and the other is at the chronic phase. Sequence analysis of reverse transcription-polymerase chain reaction products showed the presence of BCR-ABL fusion transcript e19a2. This finding suggests that CML carrying mu-BCR breakpoint may exhibit a clinical course similar to typical CML.
摘要
本报告描述了两名慢性髓性白血病（CML）患者：其中一名发展为加速期CML，诊断8年后死亡，另一名处于慢性期。逆转录-聚合酶链反应产物的序列分析显示存在BCR-ABL融合转录本e19a2。这一发现表明，携带μ-BCR断点的CML可能表现出与典型CML相似的临床病程。
相似文献
1
e19a2 BCR-ABL fusion transcript in typical chronic myeloid leukaemia: a report of two cases.
J Clin Pathol. 2006 Oct;59(10):1102-3. doi: 10.1136/jcp.2005.029595.
2
E355G mutation appearing in a patient with e19a2 chronic myeloid leukaemia resistant to imatinib.
J Clin Pathol. 2010 Aug;63(8):737-40. doi: 10.1136/jcp.2010.078311.
3
Comprehensive analysis of BCR/ABL variants in chronic myeloid leukemia patients using multiplex RT-PCR.
Clin Lab. 2012;58(5-6):433-9.
4
Blast crisis of Philadelphia chromosome-positive chronic myeloid leukaemia carrying micro-bcr breakpoint (e19a2 and e191a).
Br J Haematol. 2002 Jul;118(1):251-4. doi: 10.1046/j.1365-2141.2002.03570.x.
5
[Detection and quantification of BCR-ABL transcripts in patients with chronic myeloid leukemia by real-time quantitative reverse transcriptase polymerase chain reaction].
Zhonghua Yi Xue Za Zhi. 2005 Feb 23;85(7):453-7.
6
Comprehensive analysis of BCR-ABL transcript types in Korean CML patients using a newly developed multiplex RT-PCR.
Transl Res. 2006 Nov;148(5):249-56. doi: 10.1016/j.trsl.2006.07.002.
7
Frequency of BCR-ABL fusion transcripts in Iranian patients with chronic myeloid leukemia.
Arch Iran Med. 2008 May;11(3):247-51.
8
[Study on relationship between different bcr/abl fusion transcripts and clinical manifestations in chronic myeloid leukemia].
Zhonghua Xue Ye Xue Za Zhi. 2003 Jul;24(7):347-50.
9
An accelerrated-phase CML patient with e19a2 junction of BCR/ABL gene - the first case of transplanted CML with micro bcr.
Bone Marrow Transplant. 2000 May;25(10):1109-10. doi: 10.1038/sj.bmt.1702412.
10
Variant e19a2 BCR-ABL1 fusion transcript in typical chronic myeloid leukemia.
Clin Lab. 2011;57(9-10):785-8.
引用本文的文献
1
P190 in a Patient with Philadelphia Chromosome Positive T-Cell Acute Lymphoblastic Leukemia: A Rare Case Report and Review of Literature.
Case Rep Oncol. 2021 Jul 1;14(2):1040-1050. doi: 10.1159/000516270. eCollection 2021 May-Aug.
2
Prognostic Significance of Transcript-Type in Chronic Myeloid Leukemia.
Mediterr J Hematol Infect Dis. 2020 Sep 1;12(1):e2020062. doi: 10.4084/MJHID.2020.062. eCollection 2020.
3
Dual transcripts of - & different polymorphisms in chronic myeloid leukaemia patients.
Indian J Med Res. 2016 May;143(Supplement):S136-S141. doi: 10.4103/0971-5916.191816.
4
Rapid Evolution to Blast Crisis Associated with a Q252H ABL1 Kinase Domain Mutation in e19a2 BCR-ABL1 Chronic Myeloid Leukaemia.
Case Rep Hematol. 2013;2013:490740. doi: 10.1155/2013/490740. Epub 2013 Sep 16.
5
Early Complete Molecular Response to First-Line Nilotinib in Two Patients with Chronic Myeloid Leukemia Carrying the p230 Transcript.
Case Rep Hematol. 2013;2013:871476. doi: 10.1155/2013/871476. Epub 2013 Jul 11.
6
Chronic Myeloid Leukemia with e19a2 BCR-ABL1 Transcripts and Marked Thrombocytosis: The Role of Molecular Monitoring.
Case Rep Hematol. 2012;2012:458716. doi: 10.1155/2012/458716. Epub 2012 Jul 2.
7
Identification of potential drug targets implicated in Parkinson's disease from human genome: insights of using fused domains in hypothetical proteins as probes.
ISRN Neurol. 2011;2011:265253. doi: 10.5402/2011/265253. Epub 2011 Sep 4.
8
Targeted therapy of chronic myeloid leukemia.
Biochem Pharmacol. 2010 Sep 1;80(5):584-91. doi: 10.1016/j.bcp.2010.05.001. Epub 2010 May 12.
本文引用的文献
1
Myeloproliferative disease in transgenic mice expressing P230 Bcr/Abl: longer disease latency, thrombocytosis, and mild leukocytosis.
Blood. 2003 Jul 1;102(1):320-3. doi: 10.1182/blood-2002-10-3182. Epub 2003 Mar 6.
2
Typical chronic myelogenous leukemia with e19a2 BCR/ABL transcript. Report of two cases.
Haematologica. 2002 Aug;87(8):ELT35.
3
4
5
The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
J Exp Med. 1999 May 3;189(9):1399-412. doi: 10.1084/jem.189.9.1399.
6
P230 BCR/ABL protein may be associated with an acute leukaemia phenotype.
Br J Haematol. 1998 Dec;103(4):1104-8. doi: 10.1046/j.1365-2141.1998.01098.x.
7
A new case of chronic myeloid leukemia with c3/a2 BCR/ABL junction. Is it really a distinct disease?
Blood. 1997 Jun 1;89(11):4239-41.
8
Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction).
Blood. 1996 Oct 1;88(7):2410-4.
9
New type of Bcr/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia.
Blood. 1990 Nov 1;76(9):1819-24.
Zotero 插件